colorectal cancer research hub

An open-label, multicenter, phase 1b/2 study of E7386 in combination with pembrolizumab in previously treated subjects with selected solid tumors

This study is testing new combinations of medicines (E7386 with pembrolizumab, and sometimes with lenvatinib) for advanced bowel cancer, melanoma, and liver cancer. Researchers want to see if these combinations are safe and if they can shrink tumors.

MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO

This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

This study is testing a new medicine called Fadraciclib for advanced cancers like endometrial, ovarian, and some lymphomas. It aims to see if it's safe, how it works in the body, and if it can shrink tumors or stop cancer growth. It's for adults aged 18 and over.

F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival

This study looks at a special scan called F-18 PSMA-11 PET/CT to see how well it finds liver cancer (hepatocellular carcinoma). It aims to improve how doctors see and understand this type of cancer, and how patients respond to treatment.

Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)

This study looks at a new treatment called cabozantinib for liver cancer (hepatocellular carcinoma) in people who haven't responded to previous treatments. It aims to see how well it stops the cancer from growing and if it's safe to use. Patients will take tablets.

Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC pilot study

This study is looking at a new way to treat liver cancer (hepatocellular carcinoma) when previous immune treatments haven't worked. It combines two existing medicines, Avastin and Tecentriq, with something called Fecal Microbiota Transplant (FMT) to see if it helps patients and if it's safe.

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This study is testing new combinations of medicines for advanced liver cancer (hepatocellular carcinoma) that can't be cured with surgery. It compares different drug blends to a common treatment to see which works best and is safest.

The Detection of Small Early Liver Cancer With Natural History Follow up

The SELINA study aims to find better ways to detect early liver cancer in people with and without liver scarring (cirrhosis). We hope to improve survival by finding the cancer sooner. Participants will provide samples and some will have extra scans.

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

This study is looking at a new drug (BAY 3547926) for advanced liver cancer. Researchers want to check its safety, how well it works, and find the best dose. The drug targets cancer cells with a special protein and uses a small amount of radiation to damage them.

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.

A Study of MGC026 in Participants With Advanced Solid Tumors

This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.

Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC

This study looks at a new test called Elecsys® GAAD to help doctors find liver cancer (hepatocellular carcinoma) earlier in people with liver scarring (cirrhosis). The aim is to see if this new test can improve current screening methods and help patients get treatment sooner.

Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer

This study compares a quick, safe MRI scan to standard ultrasound for finding liver cancer early in people at high risk, like those with liver scarring (cirrhosis). The aim is to see if MRI can detect cancers that ultrasound might miss, offering a better screening method.

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

This study looks at a medicine called nivolumab for liver cancer. It's for people who've had surgery or other treatment to remove their cancer, but are at high risk of it coming back. We want to see if nivolumab can stop the cancer from returning.

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

This study looks at new drug combinations for advanced liver cancer that hasn't been treated before. It compares cabozantinib with atezolizumab against a standard treatment, sorafenib, to see which works better and is safer.

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.

The European NAFLD Registry

This study aims to understand fatty liver disease (NAFLD) better. Researchers collect information and samples from patients across Europe to find new ways to detect and monitor the disease, especially how it progresses from fatty liver to more serious conditions like fibrosis.

Prospective Cohort for Early Detection of Liver Cancer

This study aims to find better ways to detect liver cancer early in people with liver scarring (cirrhosis). Researchers will collect samples and information from 3000 volunteers to develop new, more effective tests.

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

This study looks at new ways to treat liver cancer before and after surgery. We're testing two drugs, pembrolizumab and lenvatinib, alone or together, to see if they can help stop the cancer from coming back after removal. It’s for people with liver cancer that can be surgically removed.

naVIGation Invitations Liver surveillANce upTake

This study looks at new ways to help people attend vital liver scans for conditions like liver scarring or hepatitis B. It explores if special invitations and support from a Patient Navigator can improve attendance and lead to earlier cancer detection.

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.

Deep Liver Phenotyping and Immunology Study

This study aims to find better ways to spot liver cancers early, especially in people already at risk. Researchers are looking for clues in blood, urine, and liver samples that could show who might develop cancer, helping doctors treat it sooner.

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

This study is testing a new cell therapy called BOXR1030 for advanced cancers like liver, lung, and certain other solid tumours. It aims to see how safe it is and find the best dose.

An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers

This study is testing a new way to give a cancer medicine called sorafenib, which is used for certain cancers like liver, kidney, and thyroid cancer. Researchers want to see how the new version works in healthy people compared to the current medicine.

ETCABio - Evaluation of Skin Tests in Biotherapy Allergies

This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.

A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)

This study is testing a new medicine, AZD9793, for adults with advanced solid cancers, especially liver cancer. It's looking at how safe the medicine is, how it moves through the body, and if it can help shrink tumours. It's an early-stage study, meaning it's one of the first times this medicine is being used in people.

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)

This study is looking at a new way to treat liver tumours using the HistoSonics System. It checks how safe and effective this treatment is for people with primary or metastatic liver cancer. Patients will be followed for up to five years.

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.